WCLC 2025: Latest in EGFR positive NSCLC

Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours

Treatment management of favourable risk and very favourable risk patients

Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer

Key insights from head and neck research at ASCO 2025

Transforming cancer care in India: The Access Cancer Care Initiative

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance

Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC

Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC

Independent clones in CLL show oligoclonality and early evolution patterns

Breast cancer survivorship